ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Liu, Tianshu; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, Lin*复旦大学; 北京大学; 吉林大学; 青岛大学; 哈尔滨医科大学; 郑州大学; 中山大学; 中国医学科学院北京协和医院
International Journal of Cancer2023-2-15DOI: 10.1002/ijc.34296
5被引20阅读
引用收藏
分享

摘要

First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.

学科与关键词

关键词
Asian Continental Ancestry Groupgastrointestinal neoplasmsimmunotherapynivolumabstomach neoplasms
相关
加载中…
  • First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up
    Shen, L.; Bai, Y.; Lin, X.; Li, W.; Wang, J.; Zhang, X.; Pan, H.; Bai, C.; Bai, L.; Cheng, Y.; Zhang, J.; Zhong, H.; Ba, Y.; Hu, W.; Xu, R.; Guo, W.; Qin, S.; Yang, N.; Lu, J.; Chanaga, C. Amaya; Soleymani, S.; Liu, T.被引 1
  • Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial
    Xu, Jianming*; Jiang, Haiping; Pan, Yueyin; Gu, Kangsheng; Cang, Shundong; Han, Lei; Shu, Yongqian; Li, Jiayi; Zhao, Junhui; Pan, Hongming; Luo, Suxia; Qin, Yanru; Guo, Qunyi; Bai, Yuxian; Ling, Yang; Yang, Jianwei; Yan, Zhilong; Yang, Lei; Tang, Yong; He, Yifu; Zhang, Liangming; Liang, Xinjun; Niu, Zuoxing; Zhang, Jingdong; Mao, Yong; Guo, Yingmei; Peng, Bo; Li, Ziran; Liu, Ying; Wang, Yan; Zhou, HuiJAMA, 2023, 330(21): 2064-2074.
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
    Rha, Sun Young*; Oh, Do-Youn; Yanez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Li, Jin; Lowery, Maeve A.; Cil, Timucin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A.; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S.LANCET ONCOLOGY, 2023, 24(11): 1181-1195.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Cancer
发表日期
2023-02-15
卷期
第 152 卷, 第 4 期
页码
749-760
DOI
10.1002/ijc.34296
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
Ono Pharmaceutical Co. Ltd; Bristol Myers Squibb

作者

  • L

    Liu, Tianshu (第一作者)

    fudan univ

  • B

    Bai, Yuxian

    herbin med univ

查看全部 25 位作者收起作者
  • L

    Lin, Xiaoyan

    fujian med univ

  • L

    Li, Wei

    jilin univ

  • W

    Wang, Jufeng

    zhengzhou univ

  • Z

    Zhang, Xiaochun

    qingdao univ

  • P

    Pan, Hongming

  • B

    Bai, Chunmei

    peking union med coll hosp

  • B

    Bai, Li

    china pla gen hosp

  • C

    Cheng, Ying

  • Z

    Zhang, Jingdong

    liaoning canc hosp & inst

  • Z

    Zhong, Haijun

    zhejiang canc hosp

  • B

    Ba, Yi

    tianjin med univ canc inst & hosp

  • H

    Hu, Wenwei

  • X

    Xu, Ruihua

    sun yat sen univ

  • G

    Guo, Weijian

    fudan univ

  • Q

    Qin, Shukui

  • Y

    Yang, Nong

    hunan canc hosp

  • L

    Lu, Jianwei

  • S

    Shitara, Kohei

  • L

    Lei, Ming

  • L

    Li, Mingshun

  • B

    Bao, Nicole

  • C

    Chen, Tian

  • S

    Shen, Lin (通讯)

    peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417